At its most recent plenary session, the Bavarian Academy of Sciences and Humanities (BAdW) elected 14 distinguished scholars as new members. Among them are two Helmholtz Munich researchers: Prof. Erika von Mutius and Prof. Ulrike Protzer.

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious…

Dr. Kurt Schmoller from the Institute of Functional Epigenetics at Helmholtz Munich has been awarded a prestigious European Research Council (ERC) Consolidator Grant. This significant recognition supports outstanding mid-career researchers in…

Cell death is indispensable to life, as it ensures the removal of damaged or unnecessary cells. Among the many ways a cell can die, ferroptosis is a unique and regulated form of cell death. This process plays a significant role in the pathogenesis of…

Prof. Marcus Conrad, Director of the Institute of Metabolism and Cell Death at Helmholtz Munich, was awarded the ECDO Honorary Award 2024 for his pioneering research on ferroptosis. He has been a Professor at the Technical University of Munich (TUM)…

Researchers at Helmholtz Munich have identified a specific redox protein as a critical regulator of ferroptosis - a form of regulated oxidative cell death. Research into ferroptosis mechanisms has attracted considerable interest due to its potential…

Prof. Marcus Conrad, Director at the Institute of Metabolism and Cell Death at Helmholtz Munich, has been awarded the Galenus-von-Pergamon Award in the category of Basic Research. The honor recognizes his pioneering contributions to the field of…

The second "Helmholtz Summer School on Chromatin Biology: A Hands-on Expedition", organized by the Helmholtz Munich Institute of Epigenetics and Stem Cells (IES) and the Institute of Functional Epigenetics (IFE) in collaboration with the life science…

In a new study led by Dr. Daphne Cabianca, researchers of the Institute of Functional Epigenetics at Helmholtz Munich have unveiled how environmental factors, specifically fasting, can dramatically alter the spatial organization of chromatin within…

A better understanding of ferroptosis – an iron-dependent form of cell death – is an essential prerequisite for the treatment of (neuro)degenerative diseases and certain types of cancer. A team of researchers led by Dr. Kamyar Hadian from the…

Five prestigious Starting Grants from the European Research Council have been granted to researchers with Helmholtz Munich as the host institution. The funding will enable scientists at Helmholtz Munich to advance innovative projects across various…

In chronic hepatitis B, the liver contains immune cells that could destroy hepatitis B virus-infected cells but are inactive. An international team led by scientists at the Technical University of Munich and Helmholtz Munich has discovered that cells…

Prof. Michael Sattler on exploring the impact of understanding molecular disease mechanisms and advancing personalized therapies.

Researchers created a new approach to reduce the complexity of the NMR experiments and facilitate the investigation of membrane protein systems of pharmaceutical importance.

In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…

Several research groups at Helmholtz Munich are working on innovative vaccines. Two of them are about to clear a crucial hurdle before approval - fighting the Epstein-Barr virus and Hepatitis B. But how do researchers develop a vaccine?

EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts

On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…

Epigenetic changes play important roles in cancer, metabolic and aging-related diseases, but also during loss of resilience as they cause the genetic material to be incorrectly interpreted in affected cells. A major study by scientists at Helmholtz…

TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…

Epstein-Barr Virus (EBV) is widespread and very contagious: according to the World Health Association more than 90 percent of the global population are infected with this virus throughout their lives. The virus causes B and T cell lymphomas (cancer…

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called viFSP1, which sensitizes both murine and human cancer cells to cell death through ferroptosis. Ferroptosis is defined by the…

Understanding ferroptosis is essential for addressing degenerative diseases and certain cancers. Researchers, led by Dr. Kamyar Hadian from Helmholtz Munich, revealed that the Farnesoid X Receptor (FXR), activated by bile acids, serves as a master…

Prof. Ulrike Protzer and Dr. Kamyar Hadian and their teams from Helmholtz Munich received the prestigious Bavarian m4 Award, a recognition of their exceptional contributions to the advancement of future medicine and two different groundbreaking…

A team of researchers from Helmholtz Munich in cooperation with scientists at the University Hospital Münster (UKM) has uncovered a new pathway that promotes the growth of aggressive blood cancer, so-called lymphomas. Survival of many lymphomas…

The workshop of the Molecular Targets and Therapeutics centre on July 7th was a great success with over 200 external and internal participants.

An interview with Prof. Ulrike Protzer

An interview with Prof. Reinhard Zeidler

Enabling Breakthroughs in High-Resolution Structural Analysis of Therapeutic Targets and their Visualization in the Native Cellular Context

Triose phosphates (TPs) are the primary products of photosynthetic CO₂ fixation in chloroplasts, which need to be exported into the cytosol across the chloroplast inner envelope (IE) and outer envelope (OE) membranes to sustain plant growth.

A team…

During the Corona pandemic, experts from Helmholtz Munich helped to bring the situation under control as quickly as possible. Now they are preparing for the possibility of another pandemic: with new high-tech equipment and closely interlinked…

Daniel Krappmann about his new Research Unit "Signaling and Translation" at Helmholtz Munich

Researchers gain a fundamental insight for epitranscriptomics and immune response. The research group around Vigo Heissmeyer and Taku Ito-Kureha of Helmholtz Munich and Ludwig-Maximilians-Universität München has revealed the essential function of m6A…

The German Federal Ministry of Education and Research (BMBF) is funding research of new treatment strategies for preventing tissue ischemia-reperfusion injury (IRI) as part of the FERROPath consortium. Starting in July 2022, the consortium receives…

The EU grant “PerForM-REACT” supports an infrastructure in the greater Munich area for pandemic management and prevention. Helmholtz Munich will receive new equipment for a biosafety level 3 laboratory where researchers can conduct important studies…

According to a new study led by Ulrike Protzer, a breakthrough infection after two vaccinations achieves the same protective effect as an additional booster vaccination. According to the study by Helmholtz Munich, LMU and TUM, the decisive factor for…

Researchers at Helmholtz Zentrum München and the University of Bochum received this year's Erwin Schrödinger Prize in recognition of their efforts to develop a cure for parasitic diseases such as Chagas disease with a new compound. The prize is…

Helmholtz Zentrum München is coordinating a European network to train the next generation of researchers in drug development.